Pseudomonas aeruginosa is an opportunistic pathogen that can infect the lungs of cystic fibrosis (CF) patients and persist in the form of antibiotic-tolerant aggregates in the mucus. It has recently been suggested that such aggregates are formed due to restricted bacterial motility independent of the production of extracellular matrix components, and that they do not rely on an extracellular matrix for antimicrobial tolerance. However, we show here that biofilm matrix overexpression, as displayed by various clinical isolates, significantly protects P. aeruginosa aggregates against antimicrobial treatment. Alginate-overproducing mucA mutant bacteria growing in aggregates showed highly increased antibiotic tolerance compared to wild-type bacteria in aggregates. Deletion of algD in the mucA mutant strain abrogated alginate production and reversed the antibiotic tolerance displayed by the aggregates to a level similar to that observed for aggregates formed by the wild type. The P. aeruginosa ΔwspF and ΔyfiR mutant strains both overproduce Pel and Psl exopolysaccharide, and when these bacteria grew in aggregates, they showed highly increased antibiotic tolerance compared to wild-type bacteria growing in aggregates. However, the ΔwspF and ΔyfiR mutant strains, deficient in Pel/Psl production due to additional ΔpelA ΔpslBCD deletions, formed aggregates that displayed antibiotic tolerance levels close to those of wild-type aggregates. These results suggest that biofilm matrix components, such as alginate, Pel, and Psl, do play a role in the tolerance toward antimicrobials when bacteria grow as aggregates.
M icrobial biofilms are typically viewed as aggregated bacteria embedded in an extracellular matrix composed mainly of polysaccharides, extracellular DNA, and proteins (1, 2) . Work done mainly with surface-associated biofilms has suggested that bacteria in biofilms display increased antibiotic tolerance compared to planktonic microbes (3, 4) . The studies suggest that a number of different mechanisms may be involved in antibiotic tolerance of biofilms, e.g., (i) restricted antibiotic penetration in cases where the antibiotic binds to components of the biofilm matrix, (ii) the presence of bacteria in various physiological states as a result of nutrient gradients in the biofilm, and (iii) expression of specific genes which promote antimicrobial tolerance of the bacteria in the biofilm (5, 6) .
Pseudomonas aeruginosa is an opportunistic pathogen which has been extensively studied for its ability to form structured biofilm communities. P. aeruginosa infections, where the bacteria grow in the biofilm mode, occur typically in the lungs of cystic fibrosis (CF) patients and in chronic wounds, as well as on mechanical ventilator tubing and urinary catheters. When P. aeruginosa infects the lungs of CF patients, it persists in the form of aggregates in the mucus, and these are highly resilient to host immune responses and antimicrobial treatment (7) . P. aeruginosa strains isolated from chronic infections in CF patients show a distinct pattern of adaptation through mutation (8) . Upregulation of the production of biofilm matrix components is a typical feature among clinical isolates, with phenotypes typically belonging to one of two major groups, the mucoid strains, which overexpress alginate, and the rugose small-colony variants (RSCVs), which mainly overexpress Pel and Psl polysaccharides.
Mucoid P. aeruginosa strains typically harbor inactivating mutations in the mucA gene, which in turn leads to activation of algD and production of alginate (9) . Biofilms of mucoid P. aeruginosa strains are more tolerant to antibiotics than wild-type biofilms (10) , and mucoidy has been implicated in increased tolerance to host immune responses (11) .
The RSCVs massively overexpress the matrix components Pel and Psl, while pilus and flagellum genes are downregulated (12) , resulting in a wrinkly colony morphology. Clinical RSCV isolates have been shown to be more tolerant to antimicrobials than their revertant counterparts (8, 13) . Among the RSCV variants found in chronic lung infections are strains harboring loss-of-function mutations in wspF and yfiR, resulting in derepression of the di-guanylate cyclases WspR and YfiN, respectively. This in turn leads to increased production of the regulator molecule c-di-GMP and thereby increased production of biofilm matrix components, as well as a hyperadherent and autoaggregative phenotype (14, 15) . The occurrence of RSCVs has been correlated with increased risk of failure of antipseudomonal treatment (16) .
It has recently been demonstrated that P. aeruginosa bacteria can form aggregates independent of the production of exopolysaccharides in viscous environments that restrain bacterial motility, and it has been questioned if the biofilm matrix is at all important for protection against antimicrobial compounds when P. aeruginosa is present as aggregates in the viscous mucus of CF lungs (17) .
In the present report, we provide evidence that biofilm matrix overexpression, as typically found in clinical isolates, provides protection of P. aeruginosa against antimicrobials when the bacteria are growing as aggregates. This might explain the strong selection for biofilm matrix-overproducing bacteria in chronic infections that are intensively treated with antibiotics.
RESULTS
Staudinger et al. (17) recently assessed the antimicrobial tolerance of P. aeruginosa aggregates formed in gels and found that the wild-type PAO1 and a ΔpelA ΔpslBCD ΔalgD mutant strain displayed the same level of tolerance (17) . Based on these results, it was suggested that the extracellular matrix does not play a role in the antimicrobial tolerance displayed by P. aeruginosa aggregates (17) . Here, we performed investigations similar to those reported by Staudinger et al., but instead of comparing aggregate-associated antimicrobial tolerance of the P. aeruginosa wild type to that of mutants that do not produce extracellular matrix components, we compared the wild type to mutants that overproduce matrix components, as such mutants are frequently isolated from chronic infections.
Initially, we confirmed the observations reported by Staudinger et al. (17) by comparing PAO1 to a ΔpelA ΔpslBCD ΔalgD knockout mutant strain. In accordance with the results of Staudinger et al., both strains formed visually detectable aggregates (300 to 500 m) in the agar gel ( Fig. 1A ), suggesting that spatial confinement was sufficient for aggregate formation. Moreover, the aggregates formed by the wild type and the ΔpelA ΔpslBCD ΔalgD mutant strain displayed the same level of tolerance toward tobramycin and ciprofloxacin ( Fig. 1B) .
Aggregates formed by mucoid P. aeruginosa display increased tolerance to antibiotics through alginate overproduction. We then investigated antimicrobial tolerance of aggregates formed by the mucoid P. aeruginosa mucA strain, which overproduces alginate because of an inactivating mutation in the mucA gene that normally suppresses alginate expression. The mucA strain formed aggregates in a manner similar to that of the wild-type PAO1 ( Fig. 2A ). Recovery of bacteria from untreated mucA gel-encased aggregates was similar to recovery of bacteria from wild-type PAO1 aggregates, suggesting that the mucA aggregates, despite alginate overexpression, could be disassembled and the bacteria enumerated. Alginate overexpression provided a 50-fold increase in survival after treatment with tobramycin, while a 6-fold protection was measured for ciprofloxacin ( Fig. 2B ). This corresponds to observations done in surface-attached biofilms, where biofilms formed by mucoid P. aeruginosa have been shown to be more difficult to eradicate than the corresponding wild-type biofilms (18) , while the MIC values for planktonic cultures were comparable (10) . Deletion of the algD gene in the mucA background resulted in nonmucoid (A) Micrographs of aggregates encased in LB agar for PAO1, mucA mutant, resulting in mucoid colonies, and mucA ΔalgD mutant nonmucoid colonies. (B) Survival of PAO1, mucA mutant, and mucA ΔalgD mutant aggregates upon antibiotic treatment with 50 g/ml tobramycin (tobra) or 10 g/ml ciprofloxacin (cipro) for 3 h, n Ͼ 4. For details, see Fig. 1 legend. bacteria, and aggregates formed by the mucA ΔalgD mutant strain displayed the same level of sensitivity toward tobramycin as wild-type aggregates (Fig. 2B) . Ciprofloxacin tolerance was also reversed, however, but not completely to the level of the wild-type aggregates.
Aggregates formed by P. aeruginosa RSCVs display increased tolerance to antibiotics through pel and psl overexpression. To assess the antimicrobial tolerance of P. aeruginosa aggregates which significantly overproduce Pel and Psl, we tested a ΔwspF mutant strain and a ΔyfiR mutant strain, which both overproduce c-di-GMP and biofilm matrix components and display an RSCV phenotype on agar plates and hyperaggregation in planktonic cultures. In aggregates, this wrinkly colony morphology was also visible (Fig. 3A) . We observed that bacteria in aggregates formed by the ΔwspF mutant strain displayed a 30-fold increase in survival after tobramycin treatment and a 4-fold increase in survival after ciprofloxacin treatment compared to bacteria in aggregates formed by the corresponding PAO1 wild type (Fig. 3B) . We subsequently investigated if deletion of the pel and psl genes in a ΔwspF background could reduce the antimicrobial tolerance of the aggregates. The ΔpelA ΔpslBCD ΔwspF mutant strain growing in aggregates was significantly more sensitive to the tested antimicrobials than the ΔwspF mutant strain in aggregates (Fig. 3B ), underlining the importance of the Pel and Psl matrix components in protection against antimicrobials in these aggregates.
We subsequently tested the RSCV strain harboring the ΔyfiR knockout mutation. The ΔyfiR mutant strain was the only of the tested strains which exhibited a lower recovery rate from the gel-encased aggregates compared to the wild type. We believe this might be caused by tighter aggregate formation. The ΔyfiR mutant aggregates had sizes similar to those of the wild-type aggregates but were visually distinguishable by their wrinkly surface (Fig. 4A ). Therefore, survival data are presented both in absolute numbers as CFU per milliliter ( Fig. 4B ) and as fold reduction of antibiotic-treated compared to untreated aggregates (Fig. 4C) . While tobramycin reduced the survival of the aggregate-forming wild-type bacteria by more than 150-fold, survival of the aggregate-forming ΔyfiR mutant bacteria was reduced only 5-fold. In the same way, ciprofloxacin reduced survival of the aggregate-forming wild-type bacteria by 2,500fold and only 550-fold for the aggregate-forming ΔyfiR mutant bacteria. When we introduced the ΔyfiR deletion into a ΔpelA ΔpslBCD mutant background, we did not observe any difference in antibiotic tolerance between aggregates formed by PAO1 and the ΔpelA ΔpslBCD ΔyfiR mutant strain (Fig. 4D) . This corresponds to what we observed for the ΔwspF mutant strain. 
DISCUSSION
In this study, we show, in agreement with earlier studies (Staudinger at al. [17] ), that P. aeruginosa strains with or without the ability to produce biofilm matrix components can form biofilm-like aggregates when grown under conditions where motility is restricted. Contrary to previous suggestions, however, we submit that the biofilm matrix plays a role in antimicrobial tolerance of P. aeruginosa aggregates. Bacteria in aggregates formed by an alginate-overproducing mucA mutant strain showed up to a 50-fold higher tobramycin tolerance than bacteria in aggregates formed by the wild type. Bacteria in aggregates formed by Pel/Psl-overproducing ΔwspF and ΔyfiR mutant strains exhibited up to 30-fold increased antibiotic tolerance compared to bacteria in wild-type aggregates. Deletion of alginate biosynthesis genes in the mucA background and deletion of Pel/Psl biosynthesis genes in the ΔwspF and ΔyfiR backgrounds reduced the antibiotic tolerance of the aggregates to near-wild-type levels, corroborating that the antibiotic tolerance phenotypes depend on the biofilm matrix components.
We treated P. aeruginosa biofilm-like aggregates with two different antimicrobials with different modes of action and physical properties, such as charge. Evidence has been provided that the P. aeruginosa biofilm matrix blocks the penetration of charged tobramycin into the biofilm, while this is not the case for uncharged ciprofloxacin (5) . Our finding that overproduction of biofilm matrix components increases the tolerance of P. aeruginosa aggregates toward both tobramycin and ciprofloxacin may indicate that the presence of the matrix components alters the physiology of the bacteria in the aggregates, e.g., by restricting penetration of nutrients or oxygen into the aggregates.
In addition to increased antimicrobial tolerance, biofilm matrix-overproducing bacteria evidently also display increased immune evasion. Alginate has been shown to protect P. aeruginosa against human leukocyte killing (11), in addition to inhibiting pulmonary clearing and increasing bacterial load in a mucine lung infection model (19) . Psl expression is also important for reduced phagocytosis (20) . In line with this, increased immune evasion of ΔyfiR mutant strains has been reported, and it has been shown that disruption of pel and psl in a ΔyfiR mutant strain renders it as sensitive to phagocytosis by macrophages as the wild type (14) .
In conclusion, we have provided evidence that overexpression of biofilm matrix components protects P. aeruginosa aggregates against antimicrobials. This might explain the strong selection for matrix-overproducing variants in chronic infections that are intensively treated with antibiotics.
MATERIALS AND METHODS
Strains and growth medium. The bacterial strains used in this study, PAO1 and mutant derivatives, are listed in Table 1 . All strains were cultivated in LB broth and on 1% LB agar plates.
Strain constructions. The ΔpelA ΔpslBCD ΔalgD mutant was constructed by knocking out algD from the ΔpelA ΔpslBCD mutant strain used in a study by Rybtke et al. (21) , using the protocol described in reference 22, with primers Up-F (5=-GGGGACAAGTTTGTACAAAAAAGCAGGCTCACGGAACTTCCCTCGCAG AG-3=), Up-R (5=-TACCAGCAGATGCCCTCGGCCTGCAAACCAAAGATGCTGATTCGCAT-3=), Down-F (5=-CAG GCCGAGGGCATCTGC-3=), Down-R (5=-GGGGACCACTTTGTACAAGAAAGCTGGGTA-AGTACGGGTAGACCAC GTGG-3=), Seq-F (5=-CATCAAGTTGGTATCAAGTG-3=), and Seq-R: (5=-GGAACACGTGCGACGG-3=).
The ΔyfiR deletion construct and the corresponding PAO1 strain were obtained from the lab of Urs Jenal. Deletion of yfiR in a ΔpelA ΔpslBCD background was constructed using the protocol from reference 23 using primers Seq-F (5=-CGGTATAGCTGATGGAACGG-3=) and Seq-R (5=-GAAACCGAAGATCACCAGCTG-3=).
Aggregate cultivation and antibiotic tolerance assessment. Pseudomonas aeruginosa aggregates were prepared as described in reference 17 but using LB agar instead of Mueller-Hinton agar. In short, overnight cultures in LB broth of Pseudomonas aeruginosa strains were diluted and mixed with 400 l of molten 0.8% LB agar to allow 100 to 200 cells per gel plug. Gel plugs were cast in the cylinder of single-use 2.5-ml syringes and incubated for 24 h at 37°C. Gel plugs were transferred to 4 ml of saline with or without 50 g/ml tobramycin or 10 g/ml ciprofloxacin for 3 h. After treatment, gel plugs were transferred to 600 l of 0.9% saline in 1.5-ml tubes, 2 marble beads were added, and the gel plugs were disrupted by 2 cycles of 10 s at 6,000 rpm in a MagNA Lyser (Roche). Aggregates were then disrupted by 5 min of degassing and 5 min of sonication in a water bath. Subsequently, the ability of the bacteria to survive antibiotic treatment was assessed by plating on agar plates and counting of CFU after overnight incubation. All mutant strains were run alongside with and compared to the wild-type PAO1 from which they originated.
Statistical analysis. In the figures, error bars indicate the standard deviation (SD) of n biological replicates, where n Ͼ3, as indicated in the legends. P values were determined by Student's t test using GraphPad Prism version 5.0. In-frame deletion of pelA and pslBCD 21 ΔpelA ΔpslBCD ΔalgD mutant
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